Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is -4.84% lower on its value in year-to-date trading and has touched a low of $168.25 and a high of $368.29 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MDGL stock was last observed hovering at around $272.79 in the last trading session, with the day’s gains setting it 20.85%.
Currently trading at $293.64, the stock is -4.25% and -7.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.86 million and changing 7.64% at the moment leaves the stock 12.42% off its SMA200. MDGL registered 22.37% gain for a year compared to 6-month gain of 5.20%. The firm has a 50-day simple moving average (SMA 50) of $316.1374 and a 200-day simple moving average (SMA200) of $261.19495.
The stock witnessed a -5.58% loss in the last 1 month and extending the period to 3 months gives it a 36.20%, and is -13.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.23% over the week and 5.38% over the month.
Madrigal Pharmaceuticals Inc (MDGL) has around 376 employees, a market worth around $6.40B and $76.81M in sales. Profit margin for the company is -675.24%. Distance from 52-week low is 74.53% and -20.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-57.92%).
with sales reaching $94.65M over the same period.The EPS is expected to shrink by -17.91% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Madrigal Pharmaceuticals Inc (MDGL) Top Institutional Holders
351.0 institutions hold shares in Madrigal Pharmaceuticals Inc (MDGL), with institutional investors hold 115.68% of the company’s shares. The shares outstanding are 21.81M, and float is at 18.39M with Short Float at 22.33%. Institutions hold 105.77% of the Float.
The top institutional shareholder in the company is JANUS HENDERSON GROUP PLC with over 2.49 million shares valued at $696.33 million. The investor’s holdings represent 12.4278% of the MDGL Shares outstanding. As of 2024-06-30, the second largest holder is AVORO CAPITAL ADVISORS LLC with 2.06 million shares valued at $575.88 million to account for 10.277 of the shares outstanding. The other top investors are BAKER BROS. ADVISORS LP which holds 1.97 million shares representing 9.8722% and valued at over $553.2 million, while RTW INVESTMENTS, LP holds 9.5786 of the shares totaling 1.92 million with a market value of $536.75 million.
Madrigal Pharmaceuticals Inc (MDGL) Insider Activity
The most recent transaction is an insider sale by Kelley Shannon T, the company’s General Counsel. SEC filings show that Kelley Shannon T sold 277 shares of the company’s common stock on Jan 17 ’25 at a price of $273.41 per share for a total of $75735.0. Following the sale, the insider now owns 7705.0 shares.
Madrigal Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 17 ’25 that Waltermire Robert E. (Senior VP, Chief Pharma Dev.) sold a total of 442 shares of the company’s common stock. The trade occurred on Jan 17 ’25 and was made at $273.41 per share for $0.12 million. Following the transaction, the insider now directly holds 5058.0 shares of the MDGL stock.
Still, SEC filings show that on Jan 17 ’25, Taub Rebecca (Pres., R&D, and CMO) disposed off 1,689 shares at an average price of $273.41 for $0.46 million. The insider now directly holds 457,310 shares of Madrigal Pharmaceuticals Inc (MDGL).
